Current Report Filing (8-k)
25 June 2021 - 6:41AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 22, 2021
|
INMUNE
BIO INC.
|
|
|
(Exact
name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
incorporation)
|
|
|
|
Identification
No.)
|
1200
Prospect Street, Suite 525, La Jolla, CA 92037
(Address
of Principal Executive Offices) (Zip Code)
(858)
964 3720
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.001 per shares
|
|
INMB
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
As
previously reported on a Current Report on Form 8-K that was filed with the Securities and Exchange Commission on June 3, 2021, on June
1, 2021, the stockholders of INmune Bio, Inc. (the
“Company”) approved the Company’s 2021 Stock Incentive Plan (the “2021 Plan”), pursuant to which 2,000,000
shares of the Company’s common stock will be made available for issuance under the 2021 Plan.
On
January 22, 2021, the Compensation Committee of the Board of Directors of the Company approved the issuance an option for each of the
non-employee directors to purchase an aggregate of 95,125 shares of the Company’s common stock. Each non-employee director (“Optionee”)
was granted an option to purchase 19,025 shares of the Company’s common stock. The options shall vest quarterly over three years
and have an exercise price of $17.49 per share. The Options were granted from the 2021 Plan. The Company will execute a stock option
agreement with each Optionee.
On January 22,
2021, the Compensation Committee of the Board of Directors of the Company approved the issuance of an option to Ramond J. Tesi, the Company’s
Chief Executive Officer, to purchase 70,663 shares of the Company’s common stock and the issuance of an option to David Moss, the
Company’s Chief Financial Officer, to purchase 70,663 shares of the common stock. The options granted to Dr. Tesi and Mr. Moss have
at an exercise price of $17.49 per share and, subject to the terms of the 2021 Plan and the governing option award agreement, twenty-five
percent of the option granted Dr. Tesi and Mr. Moss will vest 12 months from the Grant Date and thereafter the reaming unvested option
will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Officer is 100% vested
which shall occur on the four-year anniversary of the Grant Date. The options were granted from
the 2021 Plan. The Company will execute a stock option agreement with Dr. Tesi and Mr. Moss.
The
option grants referenced above are qualified by reference to the form of option agreement which is being filed as exhibit to this Current
Report on Form 8-K.
Item
9.01 Financial Statements and Exhibits.
(d)
The
following exhibits are being filed herewith.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INMUNE
BIO INC.
|
|
|
Date:
June 24, 2021
|
By:
|
/s/
David Moss
|
|
|
David
Moss
|
|
|
Chief
Financial Officer
|
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2023 to Jul 2024